Yahoo Finance • 3 months ago

Rhythm Pharmaceuticals, Inc. (RYTM): Short Seller Sentiment is Bearish

We recently compiled a list of the 14 Worst 52-Week High Stocks to Buy According to Short Sellers.In this article, we are going to take a look at where Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) stands against the other 52-week high stocks... Full story

Yahoo Finance • 3 months ago

RA Capital Management L.P. Increases Stake in Janux Therapeutics Inc

Overview of Recent Transaction On September 12, 2024, RA Capital Management L.P., a prominent investment firm, executed a significant transaction by acquiring an additional 1,577,341 shares of Janux Therapeutics Inc (NASDAQ:JANX). This mo... Full story

Yahoo Finance • 7 months ago

Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. IMCIVREE expected to be funded and available for use in England and Wales within three months through the National Health Service in specialist centres BOSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmace... Full story

Yahoo Finance • 8 months ago

Jim Cramer Portfolio: 11 Latest Stocks to Buy

In this article, we will take a detailed look at Jim Cramer Portfolio: 11 Latest Stocks to Buy. If you want to skip our detailed analysis on Jim Cramer's latest thoughts about the economy and see the top 5 stocks in this list, click Jim Cr... Full story

Yahoo Finance • 10 months ago

EVP Yann Mazabraud Sells 2,551 Shares of Rhythm Pharmaceuticals Inc

On February 13, 2024, Yann Mazabraud, EVP, Head of International at Rhythm Pharmaceuticals Inc, executed a sale of 2,551 shares of the company. The transaction was filed with the SEC and can be found through this SEC Filing. Warning! Guru... Full story

Yahoo Finance • 12 months ago

Insider Sell: Rhythm Pharmaceuticals CTO Joseph Shulman Sells 12,941 Shares

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity, has reported an insider sell according to a recent... Full story

Yahoo Finance • last year

Insider Sell Alert: CFO Hunter Smith Sells 27,026 Shares of Rhythm Pharmaceuticals Inc (RYTM)

In a recent transaction on December 6, 2023, Hunter Smith, the Chief Financial Officer (CFO) of Rhythm Pharmaceuticals Inc, sold a significant number of shares in the company. The insider disposed of 27,026 shares of Rhythm Pharmaceuticals... Full story

Yahoo Finance • last year

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

BOSTON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesi... Full story

Yahoo Finance • last year

Rhythm Pharmaceuticals Inc (RYTM) Reports Q3 2023 Financial Results

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) reported a net revenue of $22.5 million from global sales of IMCIVREE (setmelanotide) in Q3 2023. The company has more than 100 international patients on reimbursed IMCIVREE therapy. RYTM's Phase 3... Full story

Yahoo Finance • last year

Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update

-- Third quarter 2023 net revenue from global sales of IMCIVREE® (setmelanotide) of $22.5 million -- -- More than 100 international patients on reimbursed IMCIVREE therapy -- -- Phase 3 hypothalamic obesity trial on track to be fully enr... Full story

Yahoo Finance • last year

Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)

-- CADTH recommends reimbursement for weight management in adult and pediatric patients six years of age and older with obesity due to Bardet-Biedl syndrome (BBS)​ -- -- Recommendation based on demonstrated clinical benefit in Phase 3 tri... Full story

Yahoo Finance • last year

Rhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023

BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesi... Full story

Yahoo Finance • last year

Rhythm Pharmaceuticals Presents Data from its Long-term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Year at ObesityWeek® 2023

-- Patients with hypothalamic obesity (n=12) achieved mean BMI reduction of 25.5% at one year on setmelanotide treatment -- -- Three of 11 pediatric patients with hypothalamic obesity achieved normal weight at one year based on NIH, WHO w... Full story

Yahoo Finance • last year

Rhythm Pharmaceuticals Announces Six Abstracts to be Presented at The Obesity Society’s Annual Meeting at ObesityWeek ®

BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesi... Full story

Yahoo Finance • last year

Rhythm Pharmaceuticals Presents New Data at ESPE 2023

BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obes... Full story

Yahoo Finance • last year

Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity

BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obes... Full story

Yahoo Finance • last year

Rhythm Pharmaceuticals Announces Update to September Conference Participation

BOSTON, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obes... Full story

Yahoo Finance • last year

Rhythm Pharmaceuticals Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome

BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obes... Full story

Yahoo Finance • last year

Rhythm Pharmaceuticals to Present at Investor Conferences in September

BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesi... Full story

Yahoo Finance • last year

Rhythm Pharmaceuticals to Report Second Quarter 2023 Financial Results on Tuesday, August 1, 2023

BOSTON, July 18, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesi... Full story